Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026838 (
spasticity
)
6,471
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We report bi-allelic pathogenic
HPDL
variants as a cause of a progressive, pediatric-onset spastic movement disorder with variable clinical presentation. The single-exon gene
HPDL
encodes a protein of unknown function with sequence similarity to 4-hydroxyphenylpyruvate dioxygenase. Exome sequencing studies in 13 families revealed bi-allelic
HPDL
variants in each of the 17 individuals affected with this clinically heterogeneous autosomal-recessive neurological disorder.
HPDL
levels were significantly reduced in fibroblast cell lines derived from more severely affected individuals, indicating the identified
HPDL
variants resulted in the loss of
HPDL
protein. Clinical presentation ranged from severe, neonatal-onset neurodevelopmental delay with neuroimaging findings resembling mitochondrial encephalopathy to milder manifestation of adolescent-onset, isolated hereditary spastic paraplegia. All affected individuals developed
spasticity
predominantly of the lower limbs over the course of the disease. We demonstrated through bioinformatic and cellular studies that
HPDL
has a mitochondrial localization signal and consequently localizes to mitochondria suggesting a putative role in mitochondrial metabolism. Taken together, these genetic, bioinformatic, and functional studies demonstrate
HPDL
is a mitochondrial protein, the loss of which causes a clinically variable form of pediatric-onset spastic movement disorder.
...
PMID:Bi-allelic HPDL Variants Cause a Neurodegenerative Disease Ranging from Neonatal Encephalopathy to Adolescent-Onset Spastic Paraplegia. 3270 86